Merck, Roche unveil new moves for Africa growth; AbbVie, Lundbeck tout new study results;

> Merck KGaA teamed up with African healthcare providers and lawmakers for "More than a Mother," a campaign to train doctors about fertility problems and treatments, improve access to care in the field, and boost awareness among women about their options. Release

> Novo Nordisk ($NVO) won laurels for its green strategies and workplace environment, with Newsweek placing it in 15th place for corporate sustainability worldwide and Fortune naming it one of the best 100 companies for millennial employees. More | Release

> AbbVie ($ABBV) rolled out new data showing its hepatitis C drug cocktail showed a 100% cure rate in genotype 1b patients with cirrhosis, as it works to gain ground in the competitive field. Release

> Lundbeck said a new data analysis showed its long-lasting antipsychotic injection Abilify Maintena beat head-to-head rival Invega Sustenna at improving functioning and quality of life in young people with schizophrenia. Release

> In early guidance, England's cost-effectiveness watchdogs rejected Santen Pharmaceutical's Ikervis (ciclosporin) as a treatment for keratitis in dry eye patients. Report

And Finally... Roche ($RHHBY) said it is rolling out a new strategy for Africa, aiming to increase access to its drugs, first in 7 targeted countries. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.